We recently compiled a list of the 12 Best Fundamental Stocks to Buy Now. In this article, we are going to take a look at where Boston Scientific Corporation (NYSE:BSX) stands against other best fundamental stocks to buy now.
The S&P 500 index closed 0.3% lower at 6,101.24 on Friday, January 24, reversing its course after hitting a fresh intraday record earlier in the session. The Nasdaq Composite and Dow Jones Industrial Average also slipped, with the former dropping 0.5% to 19,954.30 and the latter falling 140.82 points to 44,424.25. This marked the end of a four-day winning streak for the three major indexes. The decline was largely attributed to investors taking profits, particularly in mega-cap tech stocks. Despite this, the market remains bullish, with the S&P 500 and Nasdaq posting their second consecutive positive week, rising 1.7% and 1.7% respectively. The Dow climbed 2.2% over the same period.
In other news, President Trump made headlines on Thursday by calling for interest rates to drop immediately and asking Saudi Arabia and other OPEC nations to lower the price of oil. Market participants are closely watching the President’s statements, which have had a significant impact on the market. However, the market’s optimism is largely driven by President Donald Trump’s pro-business policies, which have boosted risk assets. Investors are also relieved that the President has only made threats on the tariff front, rather than taking formal action, during his first few days in office.
READ ALSO: 12 Most Promising Green Stocks According to Hedge Funds and 10 Worst Performing Energy Stocks in 2024.
In an interview with CNBC on January 23, Mike Bailey, Director of Research at FBB Capital Partners, discussed the current state of the market. He noted that companies have had a great quarter, which reflects the fact that the economy is doing well, people have jobs, and they’re buying things, which trickles down to the market. This, in turn, has a positive impact on the tech sector as a whole. However, Bailey advised investors to take a more nuanced approach and consider the specific fundamentals of each company.
Bailey believes that large-cap companies have the greatest opportunity to meet or exceed investor expectations for growth. He noted that while small caps are trading cheaper, they may not be the best option for long-term investments or high-conviction plays. Bailey explained that his firm’s approach is focused on identifying companies with strong earnings growth potential, and larger cap companies tend to have more resources and a stronger track record of delivering on their growth promises. However, he did acknowledge that small caps can be a good option for investors who are looking to capitalize on a short-term economic cycle or recovery.
Bailey emphasized the importance of looking beyond the top ten stocks that make up 50% of the market, which often dominate the conversation. He suggested that there are plenty of other companies that are worth considering. These companies, according to Bailey, offer a compelling combination of growth potential, valuation, and dividend yield, making them attractive options for investors looking to diversify their portfolios.
Furthermore, Bailey emphasized the importance of having a long-term perspective and not getting caught up in short-term market fluctuations. He encouraged investors to focus on the underlying fundamentals of each company and to avoid making emotional decisions based on market volatility.
Large-cap companies with stable revenue and consistent net income growth remain attractive options for investors seeking reliable returns and long-term stability.
A surgeon examining a patient’s brain in an operating room, paramedics nearby.
Our Methodology
We used Blue Chip ETFs and financial media reports to compile a list of 25 companies with strong fundamentals. We then narrowed our choices to 12 stocks with a 10-year revenue growth rate between 8% to 20% and a 10-year net income growth rate of at least 8%, informed by reputable sources, such as SeekingAlpha. Then we used Insider Monkey’s Hedge Fund database to rank 12 stocks according to the largest number of hedge fund holders, as of Q3 2024. The list is sorted in ascending order of hedge fund sentiment.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Boston Scientific Corporation (NYSE:BSX)
Number of Hedge Fund Holdings: 92
10-Year Revenue Growth Rate: 8.17%
10-Year Net Income Growth Rate: 20.06%
Boston Scientific Corporation (NYSE:BSX) is a developer, manufacturer, and marketer of medical devices that are used in a range of interventional medical specialties including cardiology, endoscopy, neurology, and urology, among other fields. The company a has diverse portfolio of products and technologies and provides it to healthcare professionals and patients worldwide.
Boston Scientific Corporation (NYSE:BSX) is investing in emerging markets and technologies, such as structural heart and electrophysiology. The company has recently launched its ACURATE Prime platform in Europe, which has shown promising results and has the potential to increase the eligible patient population by approximately 20%. Additionally, Boston Scientific Corporation (NYSE:BSX) is committed to its TAVR program in the US and is working closely with the FDA to determine the most efficient and prudent path forward. The TAVR is a procedure where a doctor replaces a damaged heart valve using a thin tube inserted through an incision in the leg, without needing major open-heart surgery. The company believes that its Prime platform, with its enhanced features and increased radial force, will play a critical role in its future success in the TAVR market.
Boston Scientific Corporation (NYSE:BSX) is also prioritizing the development of its portfolio of imaging and diagnostic technologies, including its IVUS and OCT platforms. The company’s AVVIGO+ system, which utilizes artificial intelligence to aid in the interpretation of IVUS images, has shown significant results and is expected to drive growth in the company’s imaging business. Furthermore, Boston Scientific Corporation (NYSE:BSX) is exploring opportunities to expand its offerings in the field of pulmonary embolism treatment, including its EKOS system, which has demonstrated strong clinical results. By investing in these emerging areas, the company is well-positioned to drive growth and expansion in the coming years.
Overall BSX ranks 5th on our list of the best fundamental stocks to buy now. While we acknowledge the potential of BSX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BSX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
